Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

MarketBeat

2 Dividend Kings Quietly Beating the Market This Year

These two are the calm outperformers that might have been overlooked.

Barchart

Johnson & Johnson Ordered to Pay $65.5 Million to a Woman in Talcum Powder Cancer Case

A Minnesota jury ordered Johnson & Johnson to pay $65.5 million to a mother of three who linked her cancer to long-term use of the company's talcum powder.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

What to Expect From Johnson & Johnson’s Next Quarterly Earnings Report

Investor interest is building ahead of Johnson & Johnson’s Q4 earnings, backed by positive analyst sentiment.

Barchart

Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder

A Minnesota jury has awarded $65.5 million to a woman who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing mesothelioma

The Independent UK

3 Dividend Kings Delivering Generational Income & Market-Beating Returns

3 top-performing Dividend Kings of 2025 based on their Year-to-Date percent change.

Barchart

Johnson & Johnson ordered to pay women over talcum powder cancer cases

The healthcare giant immediately announced its intention to appeal the liability verdict and compensatory damages

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

If You Bought 10 Shares of Johnson & Johnson 10 Years Ago, You’d Have This Much Today

If you bought 10 shares of Johnson & Johnson (JNJ) stock 10 years ago, this is how much it would be worth today.

GOBankingRates

Eli Lilly, Pfizer Among 19 Drugs Approved for China's Commercial Health Insurance

China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local drugmakers.

International Business Times

Applied Materials To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

MarketBeat

3 Highest-Yielding Dividend Kings To Buy, Hold, and Forget

Discover three Dividend Kings built for buy-and-forget wealth. These stable giants may quietly deliver income and growth for decades.

Barchart

Jim Cramer Recommends These 4 Dividend Stocks, Says Era Of 'Magical Investing' In AI Is 'Dead'

CNBC host Jim Cramer has become more cautious toward AI and data center stocks after seeing increasing insider selling and borrowing activity.

Benzinga

FDA poised to kill proposal that would require asbestos testing for cosmetics

RFK Jr signed order withdrawing rule that would mandate testing for the cancer-linked toxin in talc-based makeup

The Guardian - US

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Johnson & Johnson Stock Outperforming the S&P 500?

Johnson & Johnson has outpaced the S&P 500 over the past year, and analysts remain optimistic about the healthcare stock's growth potential ahead.

Benzinga

What's Going On With Johnson & Johnson Stock On Wednesday?

Johnson Johnson (NYSE:JNJ) stock has surged almost 42.9% in the year to date, approximately 35% in 6 months, and 8.6% in one month.

Benzinga

Healthcare ETFs Trounce Tech, Grab Billions As Big Money Flees Bubble Fears

A powerful rotation into healthcare is taking shape across global markets, with investors pouring money into sector ETFs at one of the fastest clips this year. What started as a cautious move toward defensive stability has quickly morphed into a broader enthusiasm for biotech, pharma and healthcare-services names – helped…

MarketBeat

3 Smart Defensive Stocks for an Uneasy Market

Recession risks persist despite record market highs. Here are three defensive stocks—including PG, JNJ, and the DIA ETF—that can help protect your portfolio

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Court Rejects Bid To Block Kenvue's $398 Million Shareholder Payout In Tylenol Safety Dispute

On Friday, a Texas judge declined to halt an upcoming shareholder payout by Texas Attorney General Ken Paxton to restrict Kenvue Inc.'s (NYSE:KVUE) handling and marketing of Tylenol amid ongoing litigation over the product's safety for pregnant women.

Barchart

3 High-Growth Dividend Kings For Generations of Income - And Still Rated “Buy”

Dividend Kings with 20%+ YTD gains and strong analyst ratings show rare momentum, reliable income, and long-term stability across multiple sectors.

The Independent UK

The innovative new treatment which could help cancer patients avoid surgery

Bladder cancer is the ninth most common cancer in the world, the fourth most common cancer in men, and the 11th most common cancer in women

Benzinga

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.

International Business Times UK

Kimberly-Clark Snaps Up Tylenol Maker Kenvue in £30 Billion Takeover Amid Autism Controversy

Kimberly-Clark to acquire Kenvue, owner of Tylenol, in a £40 billion deal amid controversy over the painkiller's safety concerns and declining sales.

International Business Times UK

Kenvue Acquired by Kimberly-Clark in $48.7 Billion Deal to Form Consumer Staples Giant

Kimberly-Clark will acquire Kenvue in a $48.7 billion cash-and-stock deal, creating a new consumer health and personal care giant combining brands like Huggies, Kleenex, Johnson's Baby, and Band-Aid.

Barchart

Johnson & Johnson Stock: Is Wall Street Bullish or Bearish?

Johnson & Johnson has delivered a standout performance in 2025, outperforming both the broader market and the healthcare sector. Analysts continue to be fairly bullish on the stock’s trajectory.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.